65,437 trials
Nerve; Disorder, Sympathetic
Primary: Time to Indication of Successful Blockade Between the Skin Conductance Numeric Value and Bilateral Thermometry. — 0.08 Seconds
Chronic Renal Failure
Primary: Decrease in Serum Levels of Phosphorus in Patients After Treatment With Intravenous Iron. — 3.47 mg/dL
Acute Pain
Primary: Change in Pain Score From Baseline to 30 Minutes Post Initiation of Drug Administration — 3.8; 3.5 score on a scale
Non-obstructive Hypertrophic Cardiomyopathy
Primary: Percentage of Participants Who Experienced at Least One Treatment Emergent Adverse Event (TEAE) — 88.9; 90.5; 68.4 percentage of participants
Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
Primary: Number of Participants Experiencing Adverse Events (AEs) — 248; 25; 31 Participants
Sarcoma
Primary: Retention — 9 Participants
Fibromyalgia
Primary: Change From Baseline to Week 14 in the Numerical Rating Scale (NRS) Weekly Average of Daily Self-reported Average Pain Severity Scores. — -1.9; -1.5 score on a scale…
Depression · Suicidal Ideation
Primary: Depression Severity — 12.9; 9.2 score on a scale
Plaque Psoriasis
Primary: Number of Subjects With Adverse Events and Serious Adverse Events — 474; 19 Participants
Pulmonary Nodule, Solitary · Pulmonary Nodule, Multiple
Primary: Reader Confidence in s-DCT Images Compared to Conventional CT (Units on a Scale) — -0.43 Units on a scale
Cutaneous Melanoma, Stage III · Cutaneous Melanoma, Stage IV
Primary: Number of Participants With Serious Adverse Events (SAEs) and/or Dose Limiting Toxicities (DLTs) — 6; 1; 0 Participants
Pain · Postoperative Pain · Pain, Acute
Primary: Overall Summed Pain Intensity Difference (SPID) — 109.5; 111.8; 108.8; 108.6 score on a scale * hours — p=0.003
Osteoarthritis · Shoulder Pain
Primary: Shoulder Pain and Disability Index (SPADI) Score — 50.3; 49 score on a scale
Osteoarthritis, Knee · Knee Osteoarthritis · Knee Arthritis
Primary: Number of Participants Classified as Responders — 102; 15 Participants — p=<0.0001
Alpha 1-Antitrypsin Deficiency
Primary: Treatment-emergent Adverse Events Related to ADVM-043 — 0; 1; 2 Participants